Mallory L Mcclure, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 22 St Paul Dr Ste 201, Chambersburg, PA 17201 Phone: 717-217-6944 Fax: 717-217-6955 |
Ms. Vicki L Wilcoxson, APRN Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 22 St Paul Dr, Chambersburg, PA 17201 Phone: 717-217-6944 Fax: 717-303-3729 |
Daniel Kosinski, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12 St Paul Dr Ste 204, Chambersburg, PA 17201 Phone: 717-217-6886 Fax: 717-217-6896 |
James E Harvey, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12 St Paul Dr, Chambersburg, PA 17201 Phone: 717-217-6886 |
John P Mcnamara, DO Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 22 St Paul Dr, Chambersburg, PA 17201 Phone: 717-217-6944 Fax: 717-303-3729 |
News Archive
Current WSU research shows stimuli-responsive nanoparticles can specifically target infections to simultaneously prevent the spread of bacteria and reduce the inflammation it causes.
Husband-and-wife doctors at the University of Virginia Cancer Center have been awarded more than $1.8 million from the National Institutes of Health for their effort to improve radiation therapy and breast surgery for patients with early-stage breast cancer.
Kidney failure is a significant risk for patients undergoing cardiopulmonary bypass surgery, radiologic testing, antibiotic therapy or in patients suffering from severe infections. More than 80 percent of patients with postoperative acute renal failure die.
Scientists at Wake Forest University Baptist Medical Center are about to embark on a human trial to test whether a new cancer treatment will be as effective at eradicating cancer in humans as it has proven to be in mice.
Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.
› Verified 5 days ago